A blended vial that co-formulates CJC-1295 (in the no DAC form) with Ipamorelin exists because researchers modeling growth-hormone (GH) physiology have long been interested in a specific idea: that two secretagogues acting on two different pituitary receptors produce a larger, cleaner GH pulse than either compound alone
Animal experiments show that the knockdown of Zdhhc7 or inhibition of APT2 to interrupt the palmitoylation-depalmitoylation cycle alleviates the symptoms of colitis in a mouse model, suggesting that the STAT3 palmitoylation cycle and its regulatory enzymes may be new therapeutic targets for colitis (142)
Investigation of combination therapies, including combinations of these peptides with each other or with other therapeutic modalities, could potentially improve therapeutic efficacy for certain applications
Moreover, it shows a visible difference to the people who use it for a short period
doi: 10.3389/fendo.2023.1238927 Received 12 June 2023 Accepted 17 July 2023 Published 02 August 2023 Volume 14 - 2023 Edited by Zongli Diao, Capital Medical University, China Reviewed by Xuefei Tian, Yale University, United States